




LOHOCLA RESEARCH CORPORATION —FIGHTING PAIN AND ADDICTION



The cost of the country’s opioid crisis is estimated to have exceeded \$1 trillion from 2001 to 2017, and is projected to cost an additional \$500 billion by 2020, according to analysis released by Altarum, a nonprofit health research and consulting institute.

Stories of addiction surround us. For many, these aren’t just news items about faraway people we’ve never encountered. For a large percentage of the population, addiction has directly impacted our friends, our family, or even ourselves. As the rate of addiction increases across the country, the odds that we will be personally affected grows stronger by the day.

Substance abuse is not a new problem, but it will require fresh solutions to produce lasting remedies. **Lohocla Research Corporation** of the

Fitzsimons Innovation Community is pioneering development of medications that prevent relapse in people addicted to alcohol. They are also creating non-addictive medications that can prevent the development of and treat chronic pain syndromes. These novel medications are focused on reducing and replacing the use of opioids for treatment of the chronic pain syndromes.

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) is very aware that innovation is needed in this area. That’s why they have provided \$6 million to Lohocla over a five-year period, and recently approved an additional supplement of approximately \$1 million for developing their alcohol relapse treatment.

Lohocla originally gained NIAAA support with the development of a molecular scaffold that can be chemically modified to direct the resultant molecules to targets involved in controlling pain and addiction cravings. Those findings were subjected to a stringent peer review before the NIAAA offered the initial funding.

In addition to support for the alcohol relapse prevention program, the National Institute on Drug Abuse has provided Lohocla nearly \$15 million over a five year period to move its medication for chronic pain into Phase 2 clinical trials. Lohocla research takes on growing importance as medical providers continue to seek alternatives to opioid based pain treatment.

“One of the most difficult transitions in developing a new medication comes between the initial basic research stage that shows the efficacy of the drug and the stage where you examine possible toxicity and safety and move into studies with humans.”

Boris Tabakoff, Ph.D, Lohocla founder

Lohocla’s founder Boris Tabakoff, Ph.D., recognizes how important funding is at this stage.

“One of the most difficult transitions in developing a new medication comes between the initial basic research stage that shows the efficacy of the drug and the stage where you examine possible toxicity and safety and move into studies with humans.”

Lohocla plans to submit applications for Investigational New Drug status for their groundbreaking medications to the FDA within the next two years. Shortly afterward, these drugs could be helping patients and changing the stories around addiction.